Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for ALTO-100 in Bipolar depression. The expected timing is based on the latest available company guidance and may change.
5/14/25- Enrollment ongoing w/ data in H2 2026. 10/20/25- Positive blinded PK data. 11/12/25:- Enrollment ongoing; H2 2026 Ph2b BPD topline expected. Blinded PK analysis showed 96% PK-positive samples. 03/16/26:- ALTO-100 Ph2b BPD trial ongoing; topline data still anticipated in 2H 2026. 05/13/26:- Enhanced eligibility measures applied; ALTO-100 Ph2b BPD topline data readout now expected Mid-2027. 08/12/26:- Ph2b bipolar depression enrollment remains ongoing. Topline data is expected Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.